By Tarun Sai Lomte Four years after ICU admission, mortality remains strikingly high in ventilated COVID-19 ARDS patients, and many survivors continue to struggle with fatigue, insomnia, functional ...

EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Updated Phase 3 ARDS Results Continue to Show Mortality Benefit On February 24, 2026, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional Pha ...

In an open-label study of 29 men, including patients with ulcerative colitis and Crohn’s disease in remission, 6 g per day of curcumin for eight weeks led to modest, transient shifts in gut microbiota ...

Acute Respiratory Distress Syndrome (ARDS) remains a major cause of morbidity and mortality in critically ill patients worldwide, despite advances in ...

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in ...

Although e-cigarettes are often considered safer than conventional cigarettes, their vapor still poisons lung cells and ...

Explore India's neonatal respiratory challenges and how simulation training can enhance preparedness and improve outcomes for newborns.

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisiona ...

On August 7, 1963, First Lady Jacqueline Kennedy Onassis delivered her youngest child via an emergency caesarean section at ...

Edesa Biotech said that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress ...

Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech, said that the results announced today align with the central ...

A 10-month-old boy with a rare bone marrow disorder receives life-saving stem cell transplant at Yashoda Hospitals, Hyderabad ...